Matching articles for "Tukysa"

In Brief: A Second Indication for Tucatinib (Tukysa) (online only)

   
The Medical Letter on Drugs and Therapeutics • February 20, 2023;  (Issue 1670)
The oral kinase inhibitor tucatinib (Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type...
The oral kinase inhibitor tucatinib (Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine (Xeloda, and generics) for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who received at least one prior anti-HER2-based regimen for metastatic disease.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8 | Show Full IntroductionHide Full Introduction

Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

   
The Medical Letter on Drugs and Therapeutics • November 16, 2020;  (Issue 1611)
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab...
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-4 | Show Full IntroductionHide Full Introduction